Antibody-drug conjugate

Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit

Retrieved on: 
Friday, April 5, 2024
Spacecraft, Antibody, ADC, Cleveland Clinic, Conjugation, JPMorgan Chase, Antibody-drug conjugate

Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody.

Key Points: 
  • Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody.
  • "We are thrilled to be selected as a finalist for this prestigious summit," said Dr. Seah Lim , Founder and CEO of Medicovestor.
  • The Life Sciences Innovation Summit, hosted by JP Morgan Asset Management, serves as a prestigious platform for leading innovators, investors, and industry experts to explore cutting-edge advancements in healthcare and life sciences.
  • During the summit, Medicovestor aims to share insights into its ADC platform development, preclinical progress, and future prospects.

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Retrieved on: 
Wednesday, March 27, 2024
Brolucizumab, Sale, Acquisition, Conjugation, Cancer, Antibody, Therapy, ADC, Antibody-drug conjugate

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rights to royalties from the commercialization of Beovu® (brolucizumab-dbll) and another asset to Novartis for a one-time cash payment of $8 million.

Key Points: 
  • Under the agreement with Novartis, Pyxis Oncology will receive an $8 million payment from Novartis.
  • Royalties previously received by Apexigen and Pyxis Oncology will be free from any reclaim rights.
  • Pyxis Oncology will record the $8 million payment in Q1 2024.
  • Pyxis Oncology retains rights to three other antibodies in development by Apexigen's licensees, which were also discovered leveraging the APXiMAB platform.

Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer

Retrieved on: 
Tuesday, April 9, 2024
UBS, Biotechnology, CFO, Business, Patient, CBC, SAN, Cancer, Spacecraft, Pleasure, Wellesley College, Conjugation, Therapy, ADC, Antibody-drug conjugate, Management

SAN DIEGO and SHANGHAI, April 8, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).

Key Points: 
  • SAN DIEGO and SHANGHAI, April 8, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).
  • Ms. Jiang joins Adcentrx from CBC Group where she was Senior Managing Director and Management Committee Member.
  • "We are delighted to welcome Meng to Adcentrx's executive leadership team," said Hui Li, Ph.D., Founder and CEO of Adcentrx.
  • "We are glad to see Meng's continued contributions to Adcentrx as Chief Financial Officer," said Fu Wei, Chief Executive Officer at CBC Group.

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR

Retrieved on: 
Thursday, April 4, 2024
Brain, Bone marrow, Drug discovery, Patient, CNS, Research, IRBM, Cancer, Doctor of Philosophy, MD, AACR, Conjugation, ADC, Antibody-drug conjugate, Compound, Pharmaceutical industry

The data will reveal insights into the novel compounds developed to address critical unmet needs in cancer treatment.

Key Points: 
  • The data will reveal insights into the novel compounds developed to address critical unmet needs in cancer treatment.
  • Potential first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in "Ph-like" B-ALL (AM E3-SG3249) demonstrated significant preclinical efficacy, representing a pioneering approach to treating hematologic cancer characterized by poor prognosis and high relapse rates, often affecting adolescents.
  • Potential best-in-class brain permeable SHP2 allosteric inhibitor (I-1000233) exhibited promising results in preclinical studies, offering a new method of treating patients with RAS-driven malignancies, including challenging brain tumors and metastases.
  • These developments reflect our deep scientific expertise and innovative spirit, underscoring IRBM's role as a frontrunner in the integrated drug discovery industry."

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR

Retrieved on: 
Thursday, April 4, 2024
Brain, Bone marrow, Drug discovery, Patient, CNS, Research, IRBM, Cancer, Doctor of Philosophy, MD, AACR, Conjugation, ADC, Antibody-drug conjugate, Compound, Pharmaceutical industry

The data will reveal insights into the novel compounds developed to address critical unmet needs in cancer treatment.

Key Points: 
  • The data will reveal insights into the novel compounds developed to address critical unmet needs in cancer treatment.
  • Potential first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in "Ph-like" B-ALL (AM E3-SG3249) demonstrated significant preclinical efficacy, representing a pioneering approach to treating hematologic cancer characterized by poor prognosis and high relapse rates, often affecting adolescents.
  • Potential best-in-class brain permeable SHP2 allosteric inhibitor (I-1000233) exhibited promising results in preclinical studies, offering a new method of treating patients with RAS-driven malignancies, including challenging brain tumors and metastases.
  • These developments reflect our deep scientific expertise and innovative spirit, underscoring IRBM's role as a frontrunner in the integrated drug discovery industry."

Adcentrx Therapeutics to Present Preclinical Data for Nectin-4 ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Monday, April 1, 2024
Biotechnology, DAR, SAN, Neoplasm, Bystander effect, Immunoglobulin G, Cancer, Spacecraft, AACR, Monomethyl auristatin E, Clinical trial, Conjugation, Therapy, ADC, Antibody-drug conjugate, Pharmaceutical industry

Preclinical data support clear differentiation of Adcentrx's platform and lead program, ADRX-0706, currently being evaluated in a Phase 1a/b clinical trial

Key Points: 
  • Preclinical data support clear differentiation of Adcentrx's platform and lead program, ADRX-0706, currently being evaluated in a Phase 1a/b clinical trial
    SAN DIEGO, April 1, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced that preclinical data for ADRX-0706 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 , taking place April 5-10, 2024, in San Diego, CA.
  • The three presentations will include preclinical data for Adcentrx's lead ADC program, ADRX-0706.
  • The preclinical data presentations show improved therapeutic window of ADRX-0706, enhanced bystander effect and improved payload delivery to Nectin-4 expressing tumors while minimizing exposure to normal tissues.
  • Details of the three AACR poster presentations are below:
    Presentation Title: Advancing a novel tubulin-inhibitor ADC technology: The Adcentrx auristatin platform offers enhanced efficacy and safety profiles compared to vedotin technology

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

Retrieved on: 
Wednesday, December 20, 2023
Immunotherapy, Rated R, Survival, Efficacy, Breast cancer, Spacecraft, ILD, Kaplan–Meier estimator, BCT, Complex conjugate, Literature, Therapy, MBC, Toxicity, Antibody-drug conjugate, TSX, Patient, PFS, ADC, Pharmaceutical industry

“We are excited with our findings of unprecedented survival and clinical benefit in very difficult-to-treat patients who failed ADCs and view our findings as a significant clinical breakthrough in the field of cancer therapy.

Key Points: 
  • “We are excited with our findings of unprecedented survival and clinical benefit in very difficult-to-treat patients who failed ADCs and view our findings as a significant clinical breakthrough in the field of cancer therapy.
  • Kaplan-Meier analysis showed median overall survival (OS) that was up to twice that reported in the literature, with some patients recording survival of over a year.
  • Progression free survival (PFS) was similar or better than that of the patients’ prior therapy in 40% of patients, highlighting clinical benefit and tolerability of the Bria-IMT™ regimen.
  • 17 of 23 patients remain alive as of today, suggesting efficacy, tolerability, and survival benefit of BriaCell’s Bria-IMT™ regimen.

Pfizer Completes Acquisition of Seagen

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NYSE, Research, Policy, Acquisition, PFE, Spacecraft, LLP, Avelumab, Investment, ADC, Brentuximab vedotin, Antibody-drug conjugate, Protein engineering, Sullivan & Cromwell, Science, Centerview Partners, Oliver Cromwell, AACR, Cancer, Death, Financial toxicity, Communication, Federal Trade Commission, Growth, Guggenheim Partners, Inc., Arnold & Porter, Conjugation, Education, Pharmaceutical industry, Fine chemical, Pfizer, Seagen

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
  • Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
  • With the addition of Seagen, Pfizer’s Oncology pipeline has doubled in size with 60 programs spanning multiple modalities, including ADCs, small molecules, bispecifics and other immunotherapies.
  • “This is a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.

Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class

Retrieved on: 
Tuesday, October 17, 2023
Antibody-drug conjugate, Spacecraft, PDX, ADC, Toxicology, HER2, Breast cancer, NMT, Medical imaging, Fine chemical, Vaccine

Myricx’s payload platform is based on proprietary potent small molecule NMT inhibitors (NMTi).

Key Points: 
  • Myricx’s payload platform is based on proprietary potent small molecule NMT inhibitors (NMTi).
  • In the poster presentation Myricx reported data for three NMTi-ADCs in its pipeline.
  • B7-H3-NMTi demonstrated complete and durable tumour regressions in multiple models of aggressive prostate cancer refractory to Topo1i-based ADCs.
  • Myricx CEO, Dr Robin Carr said: “The preclinical data generated by our three NMTi-ADCs give us confidence that the NMTi payload platform has the potential to deliver an important new ADC payload class in the treatment of solid tumours.

Veterinary Electrosurgery Market worth $120 million | MarketsandMarkets

Retrieved on: 
Tuesday, October 10, 2023
Control, Integra, Partnership, Acquisition, DACH, Bleeding, Risk, Animal, DRE, Coagulation, Olympus Corporation, Integra LifeSciences, Blood, Trauma, Anesthesia, Scar, Infection, Antibody-drug conjugate, Veterinarian, Tissue, Electrosurgery, Veterinary medicine, Symmetry, Medical device, Birth control, Dentistry, Medtronic

In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).

Key Points: 
  • In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).
  • Minimally Invasive: Electrosurgery is often minimally invasive, resulting in smaller incisions, less pain, and reduced scarring for animals post-surgery.
  • Versatility: Electrosurgical instruments can be adapted for various veterinary procedures, including soft tissue surgeries, dermatological treatments, and ophthalmic surgeries, making them versatile tools in veterinary medicine.
  • Enhanced Patient Outcomes: Overall, the advantages of electrosurgery contribute to improved patient outcomes, making it a valuable tool for modern veterinary practices and promoting the well-being of animals.